Characteristics of bone mineral metabolism in patients with stage 3-5 chronic kidney disease not on dialysis: Results of the OSERCE study

Nefrologia

Volumn 33, Issue 1, 2013, Pages 46-60

  Górriz, José L ^a   Molina, Pablo ^a,b   Bover, Jordi ^c   Barril, Guillermina ^d   Martín de Francisco, Ángel L ^e   Caravaca, Francisco ^f   Hervás, José ^g   Piñera, Celestino ^e   Escudero, Verónica ^a   Molinero, Luis M ^h  

^a HOSPITAL UNIVERSITARIO DR PESET   (Spain)

^b UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^c FUNDACIÓ PUIGVERT   (Spain)

^d HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

^e HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

^f HOSPITAL INFANTA CRISTINA   (Spain)

^g HOSPITAL UNIVERSITARIO SAN CECILIO   (Spain)

^h U Carlos III   (Spain)

Author keywords

Calcitriol; Cholecalciferol; Chronic kidney disease; CKD MBD; K DOQI guidelines; Parathyroid hormone; Phosphorous; Vitamin D

Indexed keywords

CALCIUM; PARATHYROID HORMONE; PHOSPHORUS; VITAMIN D;

AGED; ARTICLE; BONE; CHRONIC KIDNEY FAILURE; CROSS-SECTIONAL STUDY; FEMALE; HUMAN; MALE; METABOLISM; MULTICENTER STUDY; PATHOPHYSIOLOGY; PRACTICE GUIDELINE; RENAL REPLACEMENT THERAPY;

AGED; BONE AND BONES; CALCIUM; CROSS-SECTIONAL STUDIES; FEMALE; GUIDELINE ADHERENCE; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; PARATHYROID HORMONE; PHOSPHORUS; RENAL DIALYSIS; VITAMIN D;

EID: 84873731259     PISSN: 02116995     EISSN: None     Source Type: Journal    
DOI: 10.3265/Nefrologia.pre2012.Nov.11703     Document Type: Article

References (52)

1. Coresh J, Astor BC, Greene T, Eknoyan G, Levey AS. Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey. Am J Kidney Dis 2003;41:1-12.
2. Coresh J, Selvin E, Stevens LA, Manzi J, Kusek JW, Eggers P, et al. Prevalence of chronic kidney disease in the United States. JAMA 2007;298:2038-47.
3. Furuhashi T, Moroi M, Joki N, Hase H, Masai H, Kunimasa T, et al. The impact of chronic kidney disease as a predictor of major cardiac events in patients with no evidence of coronary artery disease. J Cardiol 2010;55:328-36.
4. Keith DS, Nichols GA, Gullion CM, Brown JB, Smith DH. Longitudinal follow-up and outcomes among a population with chronic kidney disease in a large managed care organization. Arch Intern Med 2004;164:659-63.
5. Moe S, Drüeke T, Cunningham J, Goodman W, Martin K, Olgaard K, et al. Kidney Disease: Improving Global Outcomes (KDIGO). Definition, evaluation, and classification of renal osteodystrophy:a position statement from Kidney Disease:Improving Global Outcomes (KDIGO). Kidney Int 2006;69:1945-53.
6. Danese MD, Belozeroff V, Smirnakis K, Rothman KJ. Consistent control of mineral and bone disorder in incident hemodialysis patients. Clin J Am Soc Nephrol 2008;3:1423-9.
7. Block GA, Klassen PS, Lazarus JM, Ofsthun N, Lowrie EG, Chertow GM. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol 2004;15:2208-18.
8. Russo D, Corrao S, Battaglia Y, Andreucci M, Caiazza A, Carlomagno A, et al. Progression of coronary artery calcification and cardiac events in patients with chronic renal disease not receiving dialysis. Kidney Int 2011;80:112-8.
9. Mizobuchi M, Towler D, Slatopolsky E. Vascular calcification:the killer of patients with chronic kidney disease. J Am Soc Nephrol 2009;20:1453-64.
10. Kalantar-Zadeh K, Kuwae N, Regidor DL, Kovesdy CP, Kilpatrick RD, Shinaberger CS, et al. Survival predictability of time-varying indicators of bone disease in maintenance hemodialysis patients. Kidney Int 2006;70:771-80.
11. Young EW, Albert JM, Satayathum S, Goodkin DA, Pisoni RL, Akiba T, et al. Predictors and consequences of altered mineral metabolism: the Dialysis Outcomes and Practice Patterns Study. Kidney Int 2005;67:1179-87.
12. Wald R, Tentori F, Tighiouart H, Zager PG, Miskulin DC. Impact of the Kidney Disease Outcomes Quality Initiative (K/DOQI) Clinical Practice Guidelines for Bone Metabolism and Disease in a large dialysis network. Am J Kidney Dis 2007;49:257-66.
13. National Kidney Foundation. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 2003;42 Suppl 3:S1-201.
14. Al Aly Z, González EA, Martin KJ, Gellens ME. Achieving K/DOQI laboratory target values for bone and mineral metabolism: an uphill battle. Am J Nephrol 2004;24:422-6.
15. Wald R, Tentori F, Tighiouart H, Zager PG, Miskulin DC. Impact of the Kidney Disease Outcomes Quality Initiative (K/DOQI) Clinical Practice Guidelines for Bone Metabolism and Disease in a large dialysis network. Am J Kidney Dis 2007;49:257-66.
16. Wazny LD, Raymond CB, Lesperance EM, Bernstein KN. Are CSN and NKF-K/DOQI mineral metabolism guidelines for hemodialysis patients achievable? Results from a provincial renal program. CANNT J 2008;18(2):36-41.
17. Maduell F, Gorriz JL, Pallardo LM, Pons R, Santiago C; Multicentric group for the study of the phosphocalcic metabolism in the community of Valencia. Assessment of phosphorus and calcium metabolism and its clinical management in hemodialysis patients in the community of Valencia. J Nephrol 2005;18:739-48.
18. Rivera F, Sánchez de la Nieta MD, Echarri R, Anaya S, Carreño A, Vozmediano MC, et al. CA-P control in haemodialysis and K/DOQI guidelines. Nefrologia 2006;26:351-7.
19. Arenas MD, Alvarez-Ude F, Gil MT, Soriano A, Egea JJ, Millán I, et al. Application of NKF-K/DOQI Clinical Practice Guidelines for Bone Metabolism and Disease:changes of clinical practices and their effects on outcomes and quality standards in three haemodialysisunits. Nephrol Dial Transplant 2006;21:1663-8.
20. Molina P, Sánchez-Pérez P, Peris A, Górriz JL, Pallardó LM. Treatment Protocol for Controlling Bone Metabolism Parameters in Hemodialysis Patients. In: Goretti Penido M (ed.). Special Problems in Hemodialysis Patients. Available at: http://www.intechopen.com/articles/show/title/treatment-protocol-for-con trolling-bone-metabolismparameters-in-hemodialysis-patients.
21. Craver L, Martínez I, Rue M, Borràs M, Martín ML, Sarró F, et al. Mineral metabolism parameters throughout chronic kidney disease stages 1-5: Achievement of K/DOQI target ranges. Nephrol Dial Transplant 2007;22:1171-6.
22. Levin A, Bakris GL, Molitch M, Smulders M, Tian J, Williams LA, et al. Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evaluate early kidney disease. Kidney Int 2007;71:31-8.
23. Ramos AM, Albalate M, Vázquez S, Caramelo C, Egido J, Ortiz A. Hyperphosphatemia and hyperparathyroidism in incident chronic kidney disease patients. Kidney Int Suppl 2008;(111):S88-93.
24. Hoy T, Fisher M, Barber B, Borker R, Stolshek B, Goodman W. Adherence to K/DOQI practice guidelines for bone metabolism and disease. Am J Manag Care 2007;13:620-5.
25. Moe SM, Drüeke TB, Block GA, Cannata-Andía JB, Elder GJ, Fukagawa, et al., on behalf of Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int Suppl 2009;(113):S1-130.
26. Torregrosa JV, Cannata-Andia J, Bover J, Caravaca F, Lorenzo V, Martín de Francisco AL, et al. SEN Guidelines. Recommendations of the Spanish Society of Nephrology for managing bone-mineral metabolic alterations in chronic renal disease patients. Nefrologia 2008;28 Suppl 1:1-22.
27. Torregrosa JV, Bover J, Cannata-Andía J, Lorenzo V, de Francisco AL, Martínez I, et al. Spanish Society of Nephrology recommendations for controlling mineral and bone disorder in chronic kidney disease patients (S.E.N.M.B.D.). Nefrologia 2011;31 (Suppl 1):3-32.
28. Floege J, Kim J, Ireland E, Chazot C, Drueke T, Francisco ALM, et al. Serum iPTH, calcium and phosphate, and the risk of mortality in a European haemodialysis population. Nephrol Dial Transplant 2011;26:1948-55.
29. Llach F, Bover J. Renal osteodystrophies. In: Brenner BM (ed.). The Kidney, ed. 6. Philadelphia: Saunders; 2000. p. 2103-86.
30. Souberbielle JC, Boutten A, Carlier MC, Chevenne D, Coumaros G, Lawson-Body E, et al. Inter-method variability in PTH measurement: Implication for the care of CKD patients. Kidney Int 2006;70:345-50.
31. De La Piedra C, Fernández E, González Casaus ML, González Parra E. Diferencias en la función de los péptidos paratiroideos. ¿Qué estamos midiendo? Nefrología 2008;2:123-8.
32. Bover J, Górriz JL, Martín de Francisco AL, Caravaca F, Barril G, Molinero LM, et al., en nombre del grupo de investigadores del estudio OSERCE. Desconocimiento de las guías K/DOQI sobre la alteración del metabolismo óseo-mineral asociada a la enfermedad renal crónica no en diÁlisis: resultados de la encuesta en el estudio multicéntrico español OSERCE. Nefrologia 2008;28:637-43.
33. Clase CM, Norman GL, Beecroft ML, Churchill DN. Albumincorrected calcium and ionized calcium in stable haemodialysis patients. Nephrol Dial Transplant 2000;15:1841-6.
34. Koenig KG, Lindberg JS, Zerwekh JE, Padalino PK, Cushner HM, Copley JB. Free and total 1,25-dihydroxyvitamin D levels in subjects with renal disease. Kidney Int 1992;41:161-5.
35. Saha H. Calcium and vitamin D homeostasis in patients with heavy proteinuria. Clin Nephrol 1994;41:290-6.
36. Wu-Wong JR, Tian J, Goltzman D. Vitamin D analogs as therapeutic agents: a clinical study update. Curr Opin Investig Drugs 2004;5:320-6.
37. Gorriz JL, Castelao AM, De Alvaro F, Cases A, Portoles J, Luño J, et al. Morbidity and mortality factors in chronic renal disease: Diabetic and non-diabetic patients (MERENA Study). Baseline data (abstract). Nephrol Dial Transplant 2005;20 Suppl 5:v 17.
38. Holick MF. Vitamin D deficiency. N Engl J Med 2007;357:266-81.
39. Rojas-Rivera J, De La PC, Ramos A, Ortiz A, Egido J. The expanding spectrum of biological actions of vitamin D. Nephrol Dial Transplant 2010;25:2850-65.
40. Michaud J, Naud J, Ouimet D, Demers C, Petit JL, Leblond FA, et al. Reduced hepatic synthesis of calcidiol in uremia. J Am Soc Nephrol 2010;21:1488-97.
41. Cannata-Andia J, Gómez-Alonso C. Vitamin D deficiency: a neglected aspect of disturbed calcium metabolism in renal failure. Nephrol Dial Transplant 2002;17:1875-8.
42. Ghazali A, Fardellone P, Pruna A, Atik A, Achard JM, Oprisiu R, et al. Is low plasma 25-(OH)vitamin D a major risk factor for hyperparathyroidism and Looser's zones independent of calcitriol? Kidney Int 1999;55:2169-77.
43. Holick MF, Binkley NC, Bischoff-Ferrari HA, Gordon CM, Hanley DA, Heaney RP. Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2011;96:1911-30.
44. Ross AC, Manson JE, Abrams SA, Aloia JF, Brannon PM, Clinton SK, et al. The 2011 report on dietary reference intakes for calcium and vitamin D from the Institute of Medicine: what clinicians need to know. J Clin Endocrinol Metab 2011;96:53-8.
45. Navaneethan SD, Schold JD, Arrigain S, Jolly SE, Jain A, Schreiber MJ Jr, et al. Low 25-hydroxyvitamin D levels and mortality in nondialysis- dependent CKD. Am J Kidney Dis 2011;58:536-43.
46. Coen G, Mantella D, Manni M, Balducci A, Nofroni I, Sardella D, et al. 25-hydroxyvitamin D levels and bone histomorphometry in hemodialysis renal osteodystrophy. Kidney Int 2005;68:1840-8.
47. Qunibi WY, Abdellatif A, Sankar S, Hamdan Z, Lin FY, Ingle J, et al. Treatment of vitamin D deficiency in CKD patients with ergocalciferol: are current K/DOQI treatment guidelines adequate? Clin Nephrol 2010;73:276-85.
48. Raggi P, Kleerekoper M. Contribution of bone and mineral abnormalities to cardiovascular disease in patients with chronic kidney disease. Clin J Am Soc Nephrol 2008;3:836-43.
49. de Boer IH, Ioannou GN, Kestenbaum B, Brunzell JD, Weiss NS. 25- Hydroxyvitamin D levels and albuminuria in the Third National Health and Nutrition Examination Survey (NHANES III). Am J Kidney Dis 2007;50:69-77.
50. Kim MJ, Frankel AH, Donaldson M, Darch SJ, Pusey CD, Hill PD, et al. Oral cholecalciferol decreases albuminuria and urinary TGF-β1 inpatients with type 2 diabetic nephropathy on established renin-angiotensin-aldosterone system inhibition. Kidney Int 2011;80:851-60.
51. Molina P, Górriz JL, Beltrán S, Ávila A, Romero R, Pallardó LM. Oral cholecalciferol decreases albuminuria and improves secondary hyperparathyroidism in non-dialysis chronic kidney disease patients. (abs) Congress of the American Journal of Nephrology Renal Week 2012. Available at: http://www.asn-online.org/scripts/download.aspx?file=/education/kidneywe ek/archives/KW12Abstracts.pdf.
52. Gracia S, Montañés R, Bover J, Cases A, Deulofeu R, Martín de Francisco AL, et al. Documento de consenso: Recomendaciones sobre la utilización de ecuaciones para la estimación del filtrado glomerular en adultos. Nefrologia 2006;26:658-65.